Stifel initiated coverage of Amylyx (AMLX) with a Buy rating and $21 price target The firm thinks avexitide’s Phase 3 study likely works, pinning 75% odds of success on that outcome, and that post-bariatric hypoglycemia has the potential to be “a large orphan opportunity,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Is AMLX a Buy, Before Earnings?
- Amylyx price target raised to $19 from $15 at BofA
- Amylyx price target raised to $19 from $18 at Mizuho
- Amylyx price target raised to $28 from $20 at H.C. Wainwright
- Buy Rating on Amylyx: Avexitide’s High Unmet Need, Strong PBH Opportunity, and Clear Phase III Catalyst Support Upside